insights_auto
展望： 72.7% 看涨·0.0% 看跌
前往“分析”标签页chevron_right
NBIX:NASDAQ
Neurocrine Biosciences, Inc
US$135.91
arrow_upward
+0.58%(+0.78) 1 天
US$135.91
0.00% (0.00)
bedtime盘后交易
休市： 10月14日, GMT-4 16:00:00 · USD
search
所有股票代码
| 股票代码 | 价格 | 涨跌额 | 涨跌幅 |
|---|
insights_auto正在为 NBIX 生成关键数据洞见…
开盘价
US$133.94
最高价
US$136.57
最低价
US$132.25
市值
138.15亿
平均成交量
129.39万
成交量
150.67万
市盈率
19.92
52 周最高价
US$186.12
52 周最低价
US$122.14
每股收益
US$6.82
Beta 版
0.40
流通股数
1.02亿
员工人数
2500
开盘价
US$133.94
最高价
US$136.57
最低价
US$132.25
市值
138.15亿
平均成交量
129.39万
成交量
150.67万
市盈率
19.92
52 周最高价
US$186.12
52 周最低价
US$122.14
每股收益
US$6.82
Beta 版
0.40
流通股数
1.02亿
员工人数
2500
新闻报道
来自网络来源和新闻合作伙伴
Investing.com India
·
9小时前
TD Cowen reiterates Neurocrine Bio stock rating on growth outlook By Investing.com
资料
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia.
The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids. Wikipedia
Neurocrine Biosciences, Inc简介